FIELD: pharmaceutics.
SUBSTANCE: described is a group of inventions including a compound by the formula I
or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, a method for inhibiting the biological activity of cyclin-dependent protein kinases CDK8/19 in a subject, a pharmaceutical composition intended for preventing or treating a disease or a disorder mediated by activation of a cyclin-dependent protein kinase CDK8/19, a method for treating a disease or a disorder mediated by activation of cyclin-dependent protein kinases CDK8/19, and an application of the above compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition for treating a disease or a disorder mediated by activation of cyclin-dependent protein kinases CDK8/19 in a subject in need of such treatment.
EFFECT: invention expands the range of means for inhibiting the biological activity of cyclin-dependent protein kinases CDK8/19.
21 cl, 9 tbl, 93 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW CDK8/19 INHIBITORS | 2018 |
|
RU2763347C2 |
| NOVEL HETEROCYCLIC COMPOUNDS AS CDK8/19 INHIBITORS | 2018 |
|
RU2739489C2 |
| CDK8/19 INHIBITORS | 2018 |
|
RU2761824C2 |
| INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2018 |
|
RU2786524C2 |
| TRICYCLIC JANUS KINASE 1 INHIBITORS, COMPOSITIONS, METHODS OF PRODUCTION AND USE THEREOF | 2019 |
|
RU2824349C2 |
| CYSTATHIONINE-γ-LYASE (CSE) INHIBITORS | 2013 |
|
RU2661879C2 |
| CYSTATHIONINE-G-LYASE (CSE) INHIBITORS | 2013 |
|
RU2640418C2 |
| CORTISTATIN ANALOGUES FOR TREATMENT OF INFLAMMATORY AND / OR IMMUNOPATHOLOGICAL DISEASES | 2014 |
|
RU2678315C2 |
| BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS FOR USE THEREOF | 2015 |
|
RU2707280C2 |
| PYRIMIDINE-SUBSTITUTED PURINE DERIVATIVES, PHARMACEUTICAL COMPOSITION BASED THEREON, METHOD OF PROTEIN KINASE INHIBITION, METHOD OF TREATING OR PREVENTING DISEASES SENSITIVE TO PROTEIN KINASE INHIBITION AND METHOD OF TREATING PROLIFERATIVE DISEASES | 2008 |
|
RU2518098C2 |
